Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 28;51(3):1598-1601.
doi: 10.3906/sag-2012-327.

SARS-CoV-2 associated rhabdomyolysis in 32 patients

Josef Finsterer  1 , Fulvio Scorza  2
Affiliations

SARS-CoV-2 associated rhabdomyolysis in 32 patients

Josef Finsterer et al. Turk J Med Sci. .

Abstract

Background/aim: This mini-review aims at summarising and discussing previous and recent findings concerning the clinical manifestations, therapeutic management, and outcome of SARS-CoV-2 associated rhabdomyolysis.

Materials and methods: Literature search in the PubMed database by applying appropriate search terms.

Results: A total of 26 articles reporting SARS-CoV-2 associated rhabdomyolysis in 32 patients were identified. Age ranged from 16 to 80 years. Four patients were female and 25 were male. Onset of rhabdomyolysis was prior to onset of COVID-19 in 7 patients, and after onset of COVID-19 in the remaining patients. Exposure to myotoxic medication was identified in 18 patients. Myotoxic drugs these patients were taking at the time rhabdomyolysis included azithromycin, hydroxy-chloroquine, placitaxel, propofol, imastinib, piperacillin and meropenem, hydrochlorothiazide, and acetaminophen. Peak creatine-kinase values ranged from 328 to >427656 U/l. The outcome was unreported in 8 cases, favourable in 15 partial, incomplete in 3 cases, and lethal in 6 cases.

Conclusion: SARS-CoV-2 associated rhabdomyolysis is rare, may be most frequently due to the side effects of myotoxic anti-COVID-19 drugs, and only rarely due to virus myositis, and may have a favourable outcome in most patients.

Keywords: myocyte necrosis; skeletal muscle; Rhabdomyolysis; coronavirus; ground glass opacities.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Abildúa Abenza Ramírez Prieto MJ Moreno Zabaleta MT Algarra Lucas R Myopathy associated with serious SARS-CoV-2 infection. Neurologia . 2020;35:706–708. - PMC - PubMed
    1. Finsterer J Scorza FA SARS-CoV-2 myopathy. Journal of Medical Virology . 2020;10 - PMC - PubMed
    1. Gilpin S Byers M Byrd A Cull J Peterson D Rhabdomyolysis as the initial presentation of SARS-CoV-2 in an adolescent. Pediatrics . 2020;10 - PubMed
    1. Singh B Kaur P Mechineni A Maroules M. Rhabdomyolysis in COVID-19: report of four cases. Cureus . 2020;12 - PMC - PubMed
    1. Cunha M Pinho I Lopes M Trigueiros F Braz S A case of corticosteroid-responsive SARS-CoV-2 related massive rhabdomyolysis. IDCases . 2020;22 - PMC - PubMed

Substances

LinkOut - more resources